Michael Kurz, MD
Family Medicine · Pleasanton, TXNPI 1073705356
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $345 and has fallen 93.1% since, to $24 in 2022.
Across 43 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$151
- Boehringer Ingelheim$79
- Merck$76
- Pfizer$71
- AstraZeneca$70
- Lilly USA, LLC$49
- plus $175 from 8 others
What the payments were for
- Food & beverage$671100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $151 |
| Boehringer Ingelheim | 4 | $79 |
| Merck | 5 | $76 |
| Pfizer | 5 | $71 |
| AstraZeneca | 5 | $70 |
| Lilly USA, LLC | 4 | $49 |
| Amgen | 2 | $33 |
| AbbVie(2 entities) | 2 | $26 |
| GSK | 2 | $25 |
| Abbott | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Johnson & Johnson | 1 | $11 |
How this compares
$671 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 30 | $1,105 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $774 |
| Tamsulosin Hcl | 17 | $127 |
| Gabapentin | 26 | $105 |
| Levothyroxine Sodium | 21 | $95 |
| Divalproex Sodium | 14 | $77 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 14 | $69 |
| Amlodipine Besylate | 23 | $48 |
| Zolpidem Tartrate | 17 | $47 |
| Losartan Potassium | 12 | $33 |
| Levetiracetam | 11 | $32 |
| Trazodone Hcl | 18 | $31 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Pleasanton
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.